Living life with Carrera, ‘no regrets’

Article

Targeting a fun-loving audience, the latest Carrera campaign continues with its “AFTER ALL, NO REGRETS” headline and showcases a series of characters in exhilarating life situations. The campaign went live in September.

Parsippany, NJ-Targeting a fun-loving audience, the latest Carrera campaign continues with its “AFTER ALL, NO REGRETS” headline and showcases a series of characters in exhilarating life situations. The campaign went live in September.

The campaign features characters that experience exciting and captivating moments with intensity and determination, accompanied at all times by Carrera eyewear as an inseparable companion. Each character seizes every opportunity to have fun and actively seeks out new challenges, new people, and new sensations. The campaign aims to identify an ideal list of the top 10 things to do in life, with no regrets.

For more articles in this issue of InDispensable, click here.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.